Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01357421 · ClinicalTrials.gov registry record · Phase 1
Effects of TT301 on Cytokine Levels Post Endotoxin Challenge
A Phase 1 study of Traumatic Brain Injury, sponsored by OPKO Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01357421 is a Phase 1 study of Traumatic Brain Injury that has completed, run by OPKO Health. The registered enrollment target is 18 participants, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01357421, a Phase 1 study of Traumatic Brain Injury, has completed, sponsored by OPKO Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effects of TT301 on cytokine levels in healthy male volunteers participating in an endotoxin challenge.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TT301
Study Locations (1)
North Carolina
- Duke Clinical Research Unit - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01357421
The ClinicalTrials.gov registry entry for NCT01357421 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (94% lower). The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Traumatic Brain Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01357421 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01357421 about?
NCT01357421 is a clinical study titled "Effects of TT301 on Cytokine Levels Post Endotoxin Challenge". This study will evaluate the effects of TT301 on cytokine levels in healthy male volunteers participating in an endotoxin challenge.
What is the current status of trial NCT01357421?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-05. Estimated completion is 2011-06.
What conditions does trial NCT01357421 study?
This clinical trial studies the following conditions: Traumatic Brain Injury.
What interventions are being tested in trial NCT01357421?
The interventions under investigation include: Placebo (DRUG), TT301 (DRUG).
Who is sponsoring clinical trial NCT01357421?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01357421 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Traumatic Brain Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury
RECRUITING · Phase 1
-
Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury
RECRUITING · Phase 1
-
Combinatory Rehabilitation Used for Substantially Helping Individuals With Traumatic Brain Injury
RECRUITING · Phase 1
-
Traumatic Brain Injury Peripheral Nerve Study
COMPLETED · Phase 1
-
Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers
COMPLETED · Phase 1
-
Functional Connectivity as a Biomarker of rTMS
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.